{"id":2985,"date":"2021-12-09T11:28:25","date_gmt":"2021-12-09T10:28:25","guid":{"rendered":"https:\/\/www.oncology-and-cytogenetic-products.com\/?p=2985"},"modified":"2021-12-09T12:51:41","modified_gmt":"2021-12-09T11:51:41","slug":"individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2","status":"publish","type":"post","link":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/","title":{"rendered":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#8217;OMS sta valutando la separazione in BA.1 e BA.2"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.9.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: justify;\">Nuova forma di variante Omicron<strong><\/strong><\/h1>\n<p>Una <strong>nuova versione della variante Omicron (B.1.1.529)<\/strong> \u00e8 stata recentemente messa sotto i riflettori dal gruppo <a href=\"https:\/\/github.com\/cov-lineages\/pango-designation\/issues\/361\">Pango-designation<\/a>, dopo che in pochissimi giorni <strong>decine di nuove rilevazioni<\/strong> sono state depositate nel database Gisaid, utilizzato dal gruppo per aggiornare costantemente la mappa delle mutazioni individuate nel mondo. I casi emersi sono stati localizzati in <strong>Sud Africa, Australia e Canada<\/strong>.<\/p>\n<p><strong>La nuova forma di Omicron condivide molte mutazioni con la variante originale, ma l\u2019alto numero di nuove mutazioni rilevate ha indotto Pango-designation ad avanzare la proposta (<a href=\"https:\/\/github.com\/cov-lineages\/pango-designation\/issues\/359\">istanza numero 359<\/a>) di separare il \u201cceppo\u201d originale Omicron in 2 varianti diverse<\/strong>: BA.1 e BA.2. Tale proposta verr\u00e0 valutata nelle prossime ore dalla Organizzazione mondiale della sanit\u00e0: date le evidenze analitiche, per\u00f2, il parere sar\u00e0 sicuramente positivo.<\/p>\n<h1>Invisibilit\u00e0 della variante Omicron BA.2<\/h1>\n<p><strong>L\u2019invisibilit\u00e0<\/strong> di questa nuova forma della variante (BA.2) <strong>\u00e8 data dall\u2019assenza di una delezione a carico del gene S (la HV69del) che rendeva la forma Omicron originale (BA.1) diagnosticabile anche da parte dei kit molecolari non specifici<\/strong> (grazie al meccanismo dell\u2019 S gene dropout citato anche nel <a href=\"https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Implications-emergence-spread-SARS-CoV-2%20B.1.1.529-variant-concern-Omicron-for-the-EU-EEA-Nov2021.pdf\">recente documento dell\u2019ECDC<\/a> ). Proprio per questo, la nuova forma circolante \u00e8 stata presto <strong>ribattezzata \u201cinvisibile\u201d<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/products\/covid-19-nucleic-acid-detection-kit-variants\/\">Il KIT PCR COVID Varianti OaCP<\/a> permette di individuare entrambe le forme circolanti di variante Omicron (BA.1 e BA.2)<\/strong> grazie all\u2019identificazione positiva di una delle mutazioni specifiche nel gene S, la N501Y, condivisa dalle due forme.<\/p>\n<p>Come gi\u00e0 notificato dall\u2019FDA, <strong>alcuni kit PCR in commercio soffriranno la presenza di queste nuove mutazioni tanto da inficiare il riconoscimento del virus SARS-CoV-2, aumentando il rischio di falsi negativi<\/strong>. <br \/>La presenza <strong>nel nostro kit di un canale prettamente dedicato alla mutazione N501Y<\/strong>, invece, permetter\u00e0 sempre una<strong> individuazione positiva del virus a prescindere dalla variante sotto esame<\/strong>.<\/p>\n<h1>Dal tracciamento delle varianti alla riduzione del rischio di falsi negativi<\/h1>\n<p>Se all\u2019inizio della pandemia la rilevazione delle varianti era strettamente correlata alle necessit\u00e0 di sequenziamento, <strong>oggi la certezza che un kit possa individuare una variante \u00e8 sempre pi\u00f9 legata al rischio di falsi negativi. <br \/><\/strong><a href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/products\/covid-19-nucleic-acid-detection-kit-variants\/\">Il nostro kit<\/a>, dunque, \u00e8<strong> consigliato anche a quei laboratori che non hanno interesse nel discriminare le varianti circolanti ma che vogliono assicurare la positiva individuazione del virus SARS-CoV-2<\/strong> nell\u2019ambito del monitoraggio territoriale.<\/p>\n<p style=\"text-align: right;\"><strong><em>Written by Simone Di Giacomo, PhD, OaCP R&amp;D Manager<\/em><\/strong><\/p>\n<p>[\/et_pb_text][et_pb_divider divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;20%&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_4,3_4&#8243; _builder_version=&#8221;4.9.3&#8243; _dynamic_attributes=&#8221;link_option_url&#8221; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; link_option_url=&#8221;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjEzNzgifX0=@&#8221; link_option_url_new_window=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/03\/Covid-19-variants.jpg&#8221; title_text=&#8221;Covid-19-variants&#8221; align=&#8221;right&#8221; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;3_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;left&#8221; custom_margin=&#8221;50px||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3 class=\"title mb-0\">CoViD-19 Nucleic Acid Detection Kit (VARIANTS)<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nuova forma di variante Omicron Una nuova versione della variante Omicron (B.1.1.529) \u00e8 stata recentemente messa sotto i riflettori dal gruppo Pango-designation, dopo che in pochissimi giorni decine di nuove rilevazioni sono state depositate nel database Gisaid, utilizzato dal gruppo per aggiornare costantemente la mappa delle mutazioni individuate nel mondo. I casi emersi sono stati [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2991,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[54],"tags":[],"class_list":["post-2985","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-insights-it"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#039;OMS sta valutando la separazione in BA.1 e BA.2 - OaCP<\/title>\n<meta name=\"description\" content=\"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#039;OMS sta valutando la separazione in BA.1 e BA.2 - OaCP\" \/>\n<meta property=\"og:description\" content=\"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\" \/>\n<meta property=\"og:site_name\" content=\"OaCP\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-09T10:28:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-09T11:51:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Andrea Faviere\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrea Faviere\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\"},\"author\":{\"name\":\"Andrea Faviere\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\"},\"headline\":\"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#8217;OMS sta valutando la separazione in BA.1 e BA.2\",\"datePublished\":\"2021-12-09T10:28:25+00:00\",\"dateModified\":\"2021-12-09T11:51:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\"},\"wordCount\":660,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png\",\"articleSection\":[\"COVID-19 Insights\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\",\"name\":\"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l'OMS sta valutando la separazione in BA.1 e BA.2 - OaCP\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png\",\"datePublished\":\"2021-12-09T10:28:25+00:00\",\"dateModified\":\"2021-12-09T11:51:41+00:00\",\"description\":\"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#8217;OMS sta valutando la separazione in BA.1 e BA.2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"name\":\"OaCP\",\"description\":\"Oncology and Cytogenetic Products\",\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\",\"name\":\"OACP IE LTD\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"width\":159,\"height\":70,\"caption\":\"OACP IE LTD\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\",\"name\":\"Andrea Faviere\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"caption\":\"Andrea Faviere\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l'OMS sta valutando la separazione in BA.1 e BA.2 - OaCP","description":"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/","og_locale":"it_IT","og_type":"article","og_title":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l'OMS sta valutando la separazione in BA.1 e BA.2 - OaCP","og_description":"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.","og_url":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/","og_site_name":"OaCP","article_published_time":"2021-12-09T10:28:25+00:00","article_modified_time":"2021-12-09T11:51:41+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png","type":"image\/png"}],"author":"Andrea Faviere","twitter_misc":{"Scritto da":"Andrea Faviere","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#article","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/"},"author":{"name":"Andrea Faviere","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08"},"headline":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#8217;OMS sta valutando la separazione in BA.1 e BA.2","datePublished":"2021-12-09T10:28:25+00:00","dateModified":"2021-12-09T11:51:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/"},"wordCount":660,"commentCount":0,"publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png","articleSection":["COVID-19 Insights"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/","name":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l'OMS sta valutando la separazione in BA.1 e BA.2 - OaCP","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png","datePublished":"2021-12-09T10:28:25+00:00","dateModified":"2021-12-09T11:51:41+00:00","description":"La nuova forma BA.2 aumenterebbe il rischio di mancato riconoscimento del virus SARS-CoV-2 da parte dei kit molecolari non specifici.","breadcrumb":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#primaryimage","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2021\/12\/Cover-Omicron-Split.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/individuata-una-nuova-forma-di-omicron-invisibile-ad-alcuni-kit-pcr-loms-sta-valutando-la-separazione-in-ba-1-e-ba-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/"},{"@type":"ListItem","position":2,"name":"Individuata una nuova forma di Omicron invisibile ad alcuni KIT PCR: l&#8217;OMS sta valutando la separazione in BA.1 e BA.2"}]},{"@type":"WebSite","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","name":"OaCP","description":"Oncology and Cytogenetic Products","publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization","name":"OACP IE LTD","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","width":159,"height":70,"caption":"OACP IE LTD"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08","name":"Andrea Faviere","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","caption":"Andrea Faviere"}}]}},"_links":{"self":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/2985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/comments?post=2985"}],"version-history":[{"count":6,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/2985\/revisions"}],"predecessor-version":[{"id":2995,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/2985\/revisions\/2995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media\/2991"}],"wp:attachment":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media?parent=2985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/categories?post=2985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/tags?post=2985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}